Date published: 2025-10-13

1-800-457-3801

SCBT Portrait Logo
Seach Input

C4orf18 Inhibitors

C4orf18 inhibitors represent a class of chemical entities tailored to modulate the activity of a protein encoded by the C4orf18 gene, which is located on chromosome 4 and initially characterized as an open reading frame (orf). The proteins encoded by genes such as C4orf18 often have elusive functions, and the development of specific inhibitors is a strategy used by researchers to understand the biological role of such proteins. Inhibitors targeting C4orf18 would bind to the protein in a manner that affects its normal function, providing insights into the protein's role within the cell. These chemical inhibitors would be the result of extensive research into the protein's structure, its interactions with other cellular constituents, and its participation in cellular processes. Detailed knowledge of the protein's three-dimensional structure and active sites, if it has enzymatic activity, would be crucial in designing molecules that can bind to C4orf18 and inhibit its function.

The pursuit of C4orf18 inhibitors would typically start with an in-depth structural and functional analysis of the C4orf18 protein. Techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy could be utilized to gain a high-resolution image of the protein's structure, revealing potential druggable pockets or binding sites. Alongside structural studies, functional assays would be crucial in determining the protein's role in the cell, whether it is involved in enzymatic reactions, cellular signaling, or other regulatory mechanisms. Once the structure and function of C4orf18 are elucidated, the information can be used to inform the design of specific inhibitors that can modulate the protein's activity.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Staurosporine is a potent, broad-spectrum kinase inhibitor that could non-selectively inhibit the activity of many kinases, including hypothetical Golgi-associated kinases.

K-252a

99533-80-9sc-200517
sc-200517B
sc-200517A
100 µg
500 µg
1 mg
$126.00
$210.00
$488.00
19
(2)

K252a is an indolocarbazole that acts as a kinase inhibitor, affecting a range of kinases by inhibiting their ATP binding site.

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$26.00
$92.00
$120.00
$310.00
$500.00
$908.00
$1821.00
46
(1)

Genistein is a tyrosine kinase inhibitor that interferes with the phosphorylation processes essential for kinase signaling.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Dasatinib is a Src-family kinase inhibitor that could affect the function of a wide variety of kinases due to the conserved nature of the ATP binding site.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Imatinib targets certain tyrosine kinases, and while it is specific for certain kinases, it could also affect other kinases.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is a PI3K inhibitor that might impact kinase signaling pathways associated with the Golgi.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK) and might affect other kinases with similar ATP binding sites.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 is an inhibitor of MEK, a kinase that acts in the MAPK/ERK pathway, which could indirectly affect Golgi-associated kinases.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 is a p38 MAPK inhibitor that might influence the activity of Golgi-associated kinases through interconnected pathways.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is another PI3K inhibitor that, by altering PI3K activity, could potentially affect Golgi-associated kinase signaling.